.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AF01_Rivaroxaban.Rivaroxaban

Information

Rivaroxaban is an oral anticoagulant that acts as a direct Factor Xa inhibitor, used to prevent and treat venous thromboembolism and stroke in patients with atrial fibrillation. It is approved and widely used today for various indications, including prophylaxis of deep vein thrombosis after hip or knee replacement surgery, treatment of deep vein thrombosis and pulmonary embolism, and risk reduction in patients with nonvalvular atrial fibrillation.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult subjects, both male and female, under fasting conditions with single oral dose administration.

References

1. Elenjickal, EJ, et al., & Mavrakanas, TA (2024). Anticoagulation in Patients with Chronic Kidney Disease. American journal of nephrology 55(2) 146–164. DOI:10.1159/000535546 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38035566

2. Stampfuss, J, et al., & Mueck, W (2013). The effect of food on the absorption and pharmacokinetics of rivaroxaban. International journal of clinical pharmacology and therapeutics 51(7) 549–561. DOI:10.5414/CP201812 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23458226

3. Mueck, W, et al., & Becka, M (2014). Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clinical pharmacokinetics 53(1) 1–16. DOI:10.1007/s40262-013-0100-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23999929

Revisions

• 06/2025 initial generated model